vs
Side-by-side financial comparison of American Homes 4 Rent (AMH) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $455.0M, roughly 1.4× American Homes 4 Rent). Royalty Pharma plc runs the higher net margin — 34.4% vs 31.7%, a 2.7% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 4.2%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 3.6%).
American Homes 4 RentAMHEarnings & Financial Report
American Homes 4 Rent, doing business as AMH, is a real estate investment trust based in Las Vegas, Nevada, that invests in single-family rental homes. As of December 31, 2019, the company owned 52,552 homes in 22 states. Its largest concentrations are in Atlanta, Dallas-Fort Worth, and Charlotte, North Carolina.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
AMH vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $455.0M | $622.0M |
| Net Profit | $144.3M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | — | 62.4% |
| Net Margin | 31.7% | 34.4% |
| Revenue YoY | 4.2% | 4.8% |
| Net Profit YoY | 0.3% | 2.9% |
| EPS (diluted) | $0.33 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $455.0M | $622.0M | ||
| Q3 25 | $478.5M | $609.3M | ||
| Q2 25 | $457.5M | $578.7M | ||
| Q1 25 | $459.3M | $568.2M | ||
| Q4 24 | $436.6M | $593.6M | ||
| Q3 24 | $445.1M | $564.7M | ||
| Q2 24 | $423.5M | $537.3M | ||
| Q1 24 | $423.6M | $568.0M |
| Q4 25 | $144.3M | $214.2M | ||
| Q3 25 | $116.8M | $288.2M | ||
| Q2 25 | $123.6M | $30.2M | ||
| Q1 25 | $128.7M | $238.3M | ||
| Q4 24 | $143.9M | $208.2M | ||
| Q3 24 | $87.6M | $544.0M | ||
| Q2 24 | $108.5M | $102.0M | ||
| Q1 24 | $128.1M | $4.8M |
| Q4 25 | — | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 50.2% | ||
| Q1 24 | — | -13.0% |
| Q4 25 | 31.7% | 34.4% | ||
| Q3 25 | 24.4% | 47.3% | ||
| Q2 25 | 27.0% | 5.2% | ||
| Q1 25 | 28.0% | 41.9% | ||
| Q4 24 | 33.0% | 35.1% | ||
| Q3 24 | 19.7% | 96.3% | ||
| Q2 24 | 25.6% | 19.0% | ||
| Q1 24 | 30.2% | 0.8% |
| Q4 25 | $0.33 | $0.49 | ||
| Q3 25 | $0.27 | $0.67 | ||
| Q2 25 | $0.28 | $0.07 | ||
| Q1 25 | $0.30 | $0.55 | ||
| Q4 24 | $0.33 | $0.46 | ||
| Q3 24 | $0.20 | $1.21 | ||
| Q2 24 | $0.25 | $0.23 | ||
| Q1 24 | $0.30 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.5M | $618.7M |
| Total DebtLower is stronger | $5.1B | $9.0B |
| Stockholders' EquityBook value | $7.0B | $9.7B |
| Total Assets | $13.2B | $19.6B |
| Debt / EquityLower = less leverage | 0.72× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.5M | $618.7M | ||
| Q3 25 | $45.6M | $938.9M | ||
| Q2 25 | $323.3M | $631.9M | ||
| Q1 25 | $69.7M | $1.1B | ||
| Q4 24 | $199.4M | $929.0M | ||
| Q3 24 | $162.5M | $950.1M | ||
| Q2 24 | $718.4M | $1.8B | ||
| Q1 24 | $124.8M | $843.0M |
| Q4 25 | $5.1B | $9.0B | ||
| Q3 25 | $4.8B | $8.9B | ||
| Q2 25 | $5.2B | $8.0B | ||
| Q1 25 | $4.9B | $7.6B | ||
| Q4 24 | $5.0B | $7.6B | ||
| Q3 24 | $4.5B | $7.6B | ||
| Q2 24 | $5.0B | $7.6B | ||
| Q1 24 | $4.5B | $6.1B |
| Q4 25 | $7.0B | $9.7B | ||
| Q3 25 | $7.2B | $9.6B | ||
| Q2 25 | $7.2B | $9.5B | ||
| Q1 25 | $7.2B | $9.8B | ||
| Q4 24 | $7.2B | $10.3B | ||
| Q3 24 | $7.0B | $10.3B | ||
| Q2 24 | $7.0B | $9.8B | ||
| Q1 24 | $7.0B | $9.9B |
| Q4 25 | $13.2B | $19.6B | ||
| Q3 25 | $13.3B | $19.3B | ||
| Q2 25 | $13.6B | $18.3B | ||
| Q1 25 | $13.3B | $17.6B | ||
| Q4 24 | $13.4B | $18.2B | ||
| Q3 24 | $12.8B | $18.0B | ||
| Q2 24 | $13.3B | $17.7B | ||
| Q1 24 | $12.8B | $16.1B |
| Q4 25 | 0.72× | 0.92× | ||
| Q3 25 | 0.68× | 0.93× | ||
| Q2 25 | 0.72× | 0.84× | ||
| Q1 25 | 0.69× | 0.78× | ||
| Q4 24 | 0.70× | 0.74× | ||
| Q3 24 | 0.64× | 0.74× | ||
| Q2 24 | 0.71× | 0.78× | ||
| Q1 24 | 0.64× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $864.3M | $827.1M |
| Free Cash FlowOCF − Capex | $823.7M | — |
| FCF MarginFCF / Revenue | 181.0% | — |
| Capex IntensityCapex / Revenue | 8.9% | — |
| Cash ConversionOCF / Net Profit | 5.99× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $1.5B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $864.3M | $827.1M | ||
| Q3 25 | $223.3M | $702.6M | ||
| Q2 25 | $271.9M | $364.0M | ||
| Q1 25 | $223.4M | $596.1M | ||
| Q4 24 | $811.5M | $742.5M | ||
| Q3 24 | $233.6M | $703.6M | ||
| Q2 24 | $274.0M | $658.2M | ||
| Q1 24 | $201.8M | $664.6M |
| Q4 25 | $823.7M | — | ||
| Q3 25 | $214.5M | — | ||
| Q2 25 | $257.7M | — | ||
| Q1 25 | $215.9M | — | ||
| Q4 24 | $777.5M | — | ||
| Q3 24 | $225.3M | — | ||
| Q2 24 | $263.3M | — | ||
| Q1 24 | $191.0M | — |
| Q4 25 | 181.0% | — | ||
| Q3 25 | 44.8% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 47.0% | — | ||
| Q4 24 | 178.1% | — | ||
| Q3 24 | 50.6% | — | ||
| Q2 24 | 62.2% | — | ||
| Q1 24 | 45.1% | — |
| Q4 25 | 8.9% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | 7.8% | — | ||
| Q3 24 | 1.9% | — | ||
| Q2 24 | 2.5% | — | ||
| Q1 24 | 2.6% | — |
| Q4 25 | 5.99× | 3.86× | ||
| Q3 25 | 1.91× | 2.44× | ||
| Q2 25 | 2.20× | 12.06× | ||
| Q1 25 | 1.74× | 2.50× | ||
| Q4 24 | 5.64× | 3.57× | ||
| Q3 24 | 2.67× | 1.29× | ||
| Q2 24 | 2.52× | 6.45× | ||
| Q1 24 | 1.58× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMH
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
